President Trump has nominated Pierre Gentin, chief legal officer of the consulting giant McKinsey & Co. since 2019, to serve ...

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" ...

As previously reported last night, Cantor Fitzgerald analyst Colin Canfield initiated coverage of five Government Technology & Space, or ...

In a report released today, Deepak Mathivanan from Cantor Fitzgerald maintained a Hold rating on Expedia (EXPE – Research Report), with a price ...

Cantor Fitzgerald reaffirmed its Overweight rating on Neurocrine Biosciences stock (NASDAQ:NBIX) with a consistent price target of $170.00. Currently trading at $150.51, the stock has shown strong ...

Cantor Fitzgerald adjusted its price target for Fortinet shares (NASDAQ:FTNT) to $115.00, an increase from the previous target of $110.00. The firm maintained a Neutral stance on the cybersecurity ...

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...

Cantor Fitzgerald lowered the firm’s price target on Cigna (CI) to $350 from $400 and keeps an Overweight rating on the shares. Cantor is confident that Cigna can correct their stop-loss pricing ...

Meanwhile, his firm, Cantor Fitzgerald has a significant presence in Ireland, with offices in Cork, Dublin and Limerick Howard Lutnick, chairman and chief executive officer of Cantor Fitzgerald ...

On Wednesday, Cantor Fitzgerald initiated coverage on Galaxy Digital Holdings Ltd (TSX:GLXY:CN) (OTC: BRPHF), assigning an Overweight rating to the company's stock with a price target of Cdn$44.00.

Cantor Fitzgerald currently has a “Overweight” rating and a $160.00 target price on the stock. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.13 per share.